Chimerix Inc (CMRX)

HEALTH CARE: HEALTH CARE SUPPLIES
SIC: PHARMACEUTICAL PREPARATIONS

2505 MERIDIAN PARKWAY, SUITE 100 DURHAM, NC 27713

Chimerix, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of oral antiviral therapeutics for various medical needs. Its lead product includes CMX001, an orally administered drug that has completed Phase II clinical trials for the prevention of cytomegalovirus infection in hematopoietic stem cell transplant recipients; and is in Phase II clinical trials for treating double-stranded DNA viruses comprising herpesviruses, adenoviruses, BK viruses, papillomaviruses, and orthopoxviruses, as well as for the treatment of smallpox.

Data as of 2020-08-01
Market Cap192.603 Million Shares Outstanding61.93 Million Avg 30-day Volume466.326 Thousand
P/E Ratio Dividend Yield EPS-1.77
Price/Sales19.326 Price cash flow ratio Price free cash flow ratio-3.5
Book Value1.63 Price to Tangible Book1.97 Alpha-0.03
Short Interest Ratio % Short Interest to Float R-squared0.134271
BETA1.8973 52-week High/Low3.885 / 1.19 Stddev0.222774
View SEC Filings from CMRX instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 0 0 (0.0%)
13F Filers holding this stock: 81 30 (1.96%)
Aggregate 13F shares on 03/31/2020: 29.826 Million 20.22 Million
Aggregate 13F shares on 12/31/2019: 31.5 Million 21.133 Million
Percent change: -5.32% -4.32%
Funds creating new positions: 9 3
Funds Adding to an existing position: 21 7
Funds closing out their position: 14 2
Funds reducing their position: 31 15
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding CMRX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CMRX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MARIO ERNEST

  • Director
10,174 2020-07-31 0

LEONARD JOHN M. PRESIDENT AND CEO

  • Officer
  • Director
525,767 2020-07-01 0

DALY JAMES M

  • Director
0 2020-06-23 0

MACHADO PATRICK

  • Director
0 2020-06-23 1

MELEMED ALLEN S. CHIEF MEDICAL OFFICER

  • Officer
0 2020-06-19 2

DEMSKI MARTHA J

  • Director
0 2020-06-18 1

MEYER ROBERT J.

  • Director
0 2020-06-16 2

GILLISS CATHERINE

  • Director
0 2020-06-11 1

GREISSING ED

  • Director
0 2020-06-11 1

MIDDLETON FRED A

  • Director
0 2020-06-11 3

MULTANI PRATIK S

  • Director
0 2020-06-11 3

SHERMAN MICHAEL A.

  • Director
0 2020-05-01 2

RENAUD RONALD C JR

  • Director
0 2020-04-29 0

ANDRIOLE MICHAEL T. CHIEF BUSINESS OFFICER

  • Officer
149,729 2020-03-16 3

NICHOLS GARRETT CHIEF MEDICAL OFFICER

  • Officer
260,066 2020-02-07 3

JAKEMAN DAVID PRINCIPAL ACCOUNTING OFFICER

  • Officer
87,876 2020-02-07 3

CANTEX PHARMACEUTICALS, INC.

  • 10% Owner
0 2019-07-29 0

TROST TIMOTHY W. SVP, CFO & SECRETARY

  • Officer
217,088 2019-05-22 0

ALRUTZ MICHAEL ALBERT PRINCIPAL EXECUTIVE OFFICER

  • Officer
156,645 2019-02-05 0

BERREY M MICHELLE PRESIDENT AND CEO

  • Officer
  • Director
0 2019-01-23 0

RICHARDSON LINDA M CHIEF COMMERCIAL OFFICER

  • Officer
54,161 2018-05-14 0

RICCIARDI LISA CHIEF OPERATING OFFICER

  • Officer
  • Director
0 2017-11-06 0

NIEDEL JAMES

  • Director
0 2017-06-28 0

ROGERS MICHAEL D. CHIEF DEVELOPMENT OFFICER

  • Officer
0 2016-01-08 0

WOLLAEGER TIMOTHY

  • Director
0 2015-06-22 0

SANDERLING VENTURE PARTNERS V, LP

  • 10% Owner
3,311,400 2014-09-12 0

SANDERLING VENTURE PARTNERS VI CO INVESTMENT FUND LP

  • 10% Owner
697,346 2014-09-05 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

MELEMED ALLEN S. - Officer CHIEF MEDICAL OFFICER

2020-06-19 A 400,000 a 400,000 0.00 direct

GREISSING ED - Director

2020-06-11 A 35,000 a 35,000 0.00 direct

DEMSKI MARTHA J - Director

2020-06-11 A 35,000 a 35,000 0.00 direct

MEYER ROBERT J. - Director

2020-06-11 A 35,000 a 35,000 0.00 direct

MULTANI PRATIK S - Director

2020-06-11 A 35,000 a 35,000 0.00 direct

MACHADO PATRICK - Director

2020-06-11 A 35,000 a 35,000 0.00 direct

GILLISS CATHERINE - Director

2020-06-11 A 35,000 a 35,000 0.00 direct

MIDDLETON FRED A - Director

2020-06-11 A 35,000 a 35,000 0.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments